Načítá se...
Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer
One of the major recent clinical advances in cancer treatment is the use of antiangiogenic drugs such as bevacizumab, sorafenib, and sunitinib. Bevacizumab, the monoclonal anti-VEGF antibody, has been approved for the first line treatment of metastatic breast cancer (MBC) when combined with taxane....
Uloženo v:
| Vydáno v: | Breast |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4540343/ https://ncbi.nlm.nih.gov/pubmed/19914541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0960-9776(09)70271-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|